Stocks · News reference

Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

Aug 3, 2026, 2:25 PMBenzinga Newsdesk

Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 12:58 PMBenzinga Newsdesk
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share
Read original at benzinga
OVID
BenzingaJul 8, 2026, 11:28 AMBenzinga Newsdesk
Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona
Read original at benzinga
OVID
SEC EDGARJul 8, 2026, 11:03 AMSEC EDGAR
8-K filing — Ovid Therapeutics Inc. (OVID)
Filed: 2026-07-08 AccNo: 0001628280-26-047584 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgar
OVID